Biswas, Pinaki
Pfizer (United States)
3 papers on CoChatORCID 0000-0002-3324-1535
Most cited papers
- Verified
Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Simpson, E. L., Sinclair, R., Forman, S., Wollenberg, A., Aschoff, R., Cork, M., Bieber, T., Thyssen, J. P., Yosipovitch, G., Flohr, C., et al. (2020) · The Lancet
Dermatology and Skin DiseasesAsthma and respiratory diseases
Cited by 522
- Verified
Empirical Fluconazole versus Placebo for Intensive Care Unit Patients: A Randomized Trial
Schuster, M. G., Edwards, J. E., Sobel, J. D., Darouiche, R. O., Karchmer, A. W., Hadley, S., Slotman, G., Panzer, H., Biswas, P., & Rex, J. H. (2008) · Annals of Internal Medicine
Antifungal resistance and susceptibilityNosocomial Infections in ICU
Cited by 210
- Verified
Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial.
Vazquez, J., Reboli, A. C., Pappas, P. G., Patterson, T. F., Reinhardt, J., Chin-Hong, P., Tobin, E., Kett, D. H., Biswas, P., & Swanson, R. (2014) · BMC Infectious Diseases
Antifungal resistance and susceptibilityFungal Infections and Studies
Cited by 101
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free